Stock Fundamentals

Glenmark Pharmaceuticals: Making a mark - Buy

Nalinakanthi V | Updated on January 12, 2018 Published on January 08, 2017




Healthy growth in major markets and focus on key therapies are positives

The year 2016 was a docile one for Indian pharma companies. Regulatory tightening by the US drug regulator, coupled with price cuts in India, did not augur well for Indian drug makers. The BSE Healthcare Index lost over 12 per cent in 2016, with some large cap stocks losing as much as over 20 per cent. But there were some that remained resilient.

The stock of Glenmark Pharma is one such; it contained the fall at less than 5 per cent. Strong growth in key markets of the US, India and Europe, driven by niche launches, has helped the stock. With a healthy product pipeline in the US and strong market position in the home market in therapies such as dermatology, respiratory and cardiology, Glenmark is well placed to sustain good growth in the medium term.

At the current price, the stock trades at about 17 times the FY18 earnings; this implies 20-25 per cent discount to peers such as Lupin and Cipla. Investors with a two-to-three year horizon can buy the stock.

The US and India are the two key markets for Glenmark, accounting for nearly 60 per cent of the company’s consolidated revenue. With a pipeline of 111 products filed in the US, of which about 64 are pending approval, Glenmark is poised to clock healthy growth in the geography. During the first half of FY 2017, the company secured approval for eight generic drugs.

In December, the company launched the generic version of cholesterol drug Zetia and has exclusive rights to sell the product for a period of six months. With brand sales of $2.3 billion for the 12 month period ended October 2016, the launch should add significantly to the company’s profitability.

The revenue in this geography grew at a healthy 27 per cent year-on-year during the first half of the fiscal, driven by new launches.

Growth strategy

Glenmark recently unveiled its medium to long term growth strategy. It plans to focus on three key therapies — dermatology, oncology and respiratory, and envisages building a portfolio of differentiated, technologically complex products such as hormones, semi solids and inhalers.

It anticipates India, the US, Europe and active pharma ingredient (API) business to contribute over 80 per cent of revenue over the next three to five years. These should hold Glenmark in good stead over the next five years.

In the home market too, the company has managed to clock healthy growth, amid challenges such as price cuts by the Indian drug regulator. Glenmark has been able to increase its market share in key therapies such as dermatology and respiratory besides chronic areas such as anti-diabetes and cardiovascular.

The company’s domestic formulation sales grew 12 per cent for the six months ended September 2016 and is expected to sustain healthy double-digit growth. In the last five years, Glenmark’s domestic revenue grew at an annualised rate of over 20 per cent.

Currently, about eight of its brands figure among the top 300 brands. Besides its prescription business, the company plans to strengthen its over-the-counter business by adding brands to its existing portfolio of VWash and Candid.

Expanding presence

Apart from India and US, Glenmark intends to expand its presence in Europe over the next five years. The company is looking to launch differentiated products with limited competition in this market. For instance, it plans to launch generic Seretide inhaler in 15 countries next year. This should help increase contribution from this geography.

Glenmark has a pipeline of eight innovative molecules — two new chemical entities and six new biological entities in various stages of development. Monetisation of these molecules, if it happens by way of out-licensing, will be positive for the company.

Though the company’s long term debt-to-equity was higher at 0.72 times as of September 2016 vis-à-vis 0.58 times as of March 2016, its net long debt-to-equity went down from 0.38 times to 0.28 times.

Published on January 08, 2017

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.